## **KEYNOTE ANNOUNCEMENT**



Morning General Session Speaker Monday, Oct. 15 from 8:55 AM - 9:35 AM



MEET THE SPEAKER
Gregory Frost, PhD
Chairman & CEO
F1 Oncology

Dr. Frost currently serves as Chairman and CEO of F1 Oncology, a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors. F1 Oncology leverages its globally integrated science, development and informatics teams located across multiple time zones to accelerate the design, high-throughput screening, discovery and development of adoptive cellular therapy (ACT) candidates. The company is developing two CAB-based ACT platforms to develop TME-

restricted CAR-T therapies for solid tumors, as well as developing highly scalable systems for global deployment, beginning in Asia.

Dr. Frost has been Managing Director of F1 BioVentures, LLC since 2015. Previously, he led the Health Sector of Intrexon Corporation, a multinational public biotechnology company, where he was responsible for expanding their oncology franchise and gene and cellular-based therapies for a number of orphan diseases. From 1999 to 2014, Dr. Frost was at Halozyme Therapeutics, a San Diego public biotechnology company he co-founded, focused on oncology biologics and medication delivery, where he served on the Board of Directors and in numerous operational roles, including Chief Scientific Officer since 2002, and CEO since 2010.

As an entrepreneur, Dr. Frost brought the founding platform technologies to Halozyme and secured the initial capital for the company. In 2012, Gregory Frost was named by Forbes as one of Americas 20 most powerful CEO's 40 and under and was a finalist for Ernst and Young's Entrepreneur of the Year in San Diego. Dr. Frost additionally serves on the Board of Directors of BioCom, a member-driven organization serving the life science community of Southern California and BioAtla, LLC.

## ADDITIONAL GENERAL SESSION HIGHLIGHTS

- Industry Partnership and Investment Strategies
- Latin America Industry Dynamics
- Expanding Florida's Life Science Footprint
- CEO Panel: Case Studies from Florida's Experts
- Legislation Impacting Florida's Life Sciences Industry

**VIEW THE FULL AGENDA**